RB pathway and therapeutic sensitivity: New insights in breast cancer and Tamoxifen therapy

Cell Cycle

Volumn 10, Issue 10, 2011, Pages 1525-

  Witkiewicz, Agnieszka K ^a   Knudsen, Erik S ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY KI 67; RETINOBLASTOMA TUMOR SUPPRESSOR PROTEIN; TAMOXIFEN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER GROWTH; CANCER RESISTANCE; CELL DISRUPTION; CELL PROLIFERATION; DRUG EFFICACY; GENE EXPRESSION; HUMAN; NONHUMAN; NOTE; PROGNOSIS; PROTEIN PHOSPHORYLATION; TREATMENT RESPONSE;

EID: 79956052500     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.10.15521     Document Type: Note

References (16)

1. Musgrove EA, et al. Nat Rev Cancer 2009; 9:631-43.
2. Johnston SR. Clin Cancer Res 2010; 16:1979-87.
3. Zilli M, et al. Biochim Biophys Acta 2009; 1795:62-81.
4. Riggins RB, et al. Cancer Lett 2007; 256:1-24.
5. Lehn S, et al. Cell Cycle 2011; 10:956-62
6. Burkhart DL, et al. Nat Rev Cancer 2008; 8:671-82.
7. Knudsen ES, et al. Nat Rev Cancer 2008; 8:714-24.
8. Arnold A, et al. J Clin Oncol 2005; 23:4215-24.
9. Templeton DJ, et al. Proc Natl Acad Sci USA 1991; 88:3033-7.
10. Gauthier ML, et al. Cancer Cell 2007; 12:479-91.
11. Ertel A, et al. Cell Cycle 2010; 9:4153-63.
12. Bosco EE, et al. J Clin Invest 2007; 117:218-28.
13. Herschkowitz JI, et al. Breast Cancer Res 2008; 10:R75.
14. Bosco EE, et al. Cell Cycle 2007; 6:667-71.
15. Jiang Z, et al. J Clin Invest 2010; 120:3296-309.
16. Sharma A, et al. J Clin Invest 2010; 120:4478-92.